What is it about?

This article is a systematic review that examines the metabolic side effects of multitarget kinase inhibitors (MKIs) - a type of drug used to treat several types of cancer. The study focuses specifically on the effects of four MKIs (Cabozantinib, Lenvatinib, Sorafenib, and Vandetanib) on the glucose and lipid metabolism of adult patients with cancer. The use of MKIs can lead to metabolic alterations, including elevation of glucose levels, worsening or new-onset hypercholesterolemia, and hypertriglyceridemia. These metabolic changes can be severe and sometimes life-threatening.

Featured Image

Why is it important?

Future clinical trials should consider routine assessment of glucose, cholesterol and triglyceride levels to prevent underdetection and underreporting of these important adverse events.

Read the Original

This page is a summary of: Metabolic adverse events of multitarget kinase inhibitors: a systematic review, Endocrine, April 2023, Springer Science + Business Media, DOI: 10.1007/s12020-023-03362-2.
You can read the full text:



The following have contributed to this page